Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Additionally, further safety data is gathered, and pharmacodynamic markers may also be developed. Traditional early phase oncology dose-finding studies. RECIST: Response Evaluation Criteria in Solid Tumors. This approach has been acceptable for cytotoxic chemotherapy drugs due to their steep dose-response relationships, their limited drug target specificity, and the willingness of patients to trade off substantial toxicity to treat serious, life-threatening diseases [2].

Bill Byrom, Anthony Everhart, Paul Cordero, Chris Garratt, Tim Meyer

JMIR Cancer 2025;11:e64611